Personal Products & Services
Compare Stocks
4 / 10Stock Comparison
RGS vs IPAR vs EL vs SKIN
Revenue, margins, valuation, and 5-year total return — side by side.
Household & Personal Products
Household & Personal Products
Household & Personal Products
RGS vs IPAR vs EL vs SKIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Personal Products & Services | Household & Personal Products | Household & Personal Products | Household & Personal Products |
| Market Cap | $68M | $3.01B | $30.80B | $118M |
| Revenue (TTM) | $233M | $1.49B | $14.84B | $296M |
| Net Income (TTM) | $114M | $201M | $-248M | $-6M |
| Gross Margin | 47.6% | 64.0% | 74.7% | 64.9% |
| Operating Margin | 10.5% | 18.0% | 6.8% | -3.6% |
| Forward P/E | 0.6x | 19.4x | 38.4x | — |
| Total Debt | $351M | $224M | $9.44B | $379M |
| Cash & Equiv. | $35M | $158M | $2.92B | $233M |
RGS vs IPAR vs EL vs SKIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| Regis Corporation (RGS) | 100 | 16.5 | -83.5% |
| Inter Parfums, Inc. (IPAR) | 100 | 173.0 | +73.0% |
| The Estée Lauder Co… (EL) | 100 | 34.8 | -65.2% |
| The Beauty Health C… (SKIN) | 100 | 9.0 | -91.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RGS vs IPAR vs EL vs SKIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RGS carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 3.5%, EPS growth 13.9%, 3Y rev CAGR -8.7%
- 3.5% revenue growth vs SKIN's -10.0%
- Lower P/E (0.6x vs 38.4x)
- 48.9% margin vs SKIN's -2.0%
IPAR is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 5 yrs, beta 0.54, yield 3.4%
- 255.2% 10Y total return vs EL's 10.8%
- Lower volatility, beta 0.54, Low D/E 20.3%, current ratio 2.99x
- Beta 0.54, yield 3.4%, current ratio 2.99x
EL plays a supporting role in this comparison — it may shine differently against other peers.
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.5% revenue growth vs SKIN's -10.0% | |
| Value | Lower P/E (0.6x vs 38.4x) | |
| Quality / Margins | 48.9% margin vs SKIN's -2.0% | |
| Stability / Safety | Beta 0.54 vs SKIN's 2.00, lower leverage | |
| Dividends | 3.4% yield, 5-year raise streak, vs EL's 2.0%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +49.9% vs SKIN's -35.9% | |
| Efficiency (ROA) | 19.4% ROA vs EL's -1.3%, ROIC 3.2% vs 6.5% |
RGS vs IPAR vs EL vs SKIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
RGS vs IPAR vs EL vs SKIN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IPAR leads in 2 of 6 categories
RGS leads 0 • EL leads 0 • SKIN leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — RGS and IPAR each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EL is the larger business by revenue, generating $14.8B annually — 63.6x RGS's $233M. RGS is the more profitable business, keeping 48.9% of every revenue dollar as net income compared to SKIN's -2.0%. On growth, RGS holds the edge at +22.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $233M | $1.5B | $14.8B | $296M |
| EBITDAEarnings before interest/tax | $29M | $291M | $1.6B | $9M |
| Net IncomeAfter-tax profit | $114M | $201M | -$248M | -$6M |
| Free Cash FlowCash after capex | $15M | $199M | $1.3B | $29M |
| Gross MarginGross profit ÷ Revenue | +47.6% | +64.0% | +74.7% | +64.9% |
| Operating MarginEBIT ÷ Revenue | +10.5% | +18.0% | +6.8% | -3.6% |
| Net MarginNet income ÷ Revenue | +48.9% | +13.5% | -1.7% | -2.0% |
| FCF MarginFCF ÷ Revenue | +6.4% | +13.3% | +8.7% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.3% | +1.8% | +4.6% | -6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -94.1% | +2.3% | -45.5% | +38.0% |
Valuation Metrics
Evenly matched — RGS and IPAR each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 0.6x trailing earnings, RGS trades at a 96% valuation discount to IPAR's 17.9x P/E. On an enterprise value basis, IPAR's 11.3x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $68M | $3.0B | $30.8B | $118M |
| Enterprise ValueMkt cap + debt − cash | $384M | $3.1B | $37.3B | $264M |
| Trailing P/EPrice ÷ TTM EPS | 0.64x | 17.93x | -27.08x | -5.69x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.38x | 38.44x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 0.53x | — | — |
| EV / EBITDAEnterprise value multiple | 16.75x | 11.33x | 20.88x | 7331.15x |
| Price / SalesMarket cap ÷ Revenue | 0.32x | 2.02x | 2.16x | 0.39x |
| Price / BookPrice ÷ Book value/share | 0.40x | 2.74x | 7.95x | 2.02x |
| Price / FCFMarket cap ÷ FCF | 5.48x | 15.80x | 45.97x | 3.17x |
Profitability & Efficiency
IPAR leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
RGS delivers a 60.4% return on equity — every $100 of shareholder capital generates $60 in annual profit, vs $-9 for SKIN. IPAR carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs EL's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +60.4% | +18.4% | -6.3% | -9.4% |
| ROA (TTM)Return on assets | +19.4% | +12.9% | -1.3% | -1.2% |
| ROICReturn on invested capital | +3.2% | +18.6% | +6.5% | -6.8% |
| ROCEReturn on capital employed | +3.9% | +23.3% | +6.3% | -4.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 4 | 7 |
| Debt / EquityFinancial leverage | 1.89x | 0.20x | 2.44x | 6.20x |
| Net DebtTotal debt minus cash | $316M | $66M | $6.5B | $146M |
| Cash & Equiv.Liquid assets | $35M | $158M | $2.9B | $233M |
| Total DebtShort + long-term debt | $351M | $224M | $9.4B | $379M |
| Interest CoverageEBIT ÷ Interest expense | 1.31x | 50.40x | 1.14x | 0.81x |
Total Returns (Dividends Reinvested)
Evenly matched — RGS and IPAR each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IPAR five years ago would be worth $14,188 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, RGS leads with a +49.9% total return vs SKIN's -35.9%. The 3-year compound annual growth rate (CAGR) favors RGS at 10.8% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +4.7% | +10.9% | -19.8% | -35.0% |
| 1-Year ReturnPast 12 months | +49.9% | -18.8% | +46.3% | -35.9% |
| 3-Year ReturnCumulative with dividends | +35.9% | -32.7% | -55.6% | -91.7% |
| 5-Year ReturnCumulative with dividends | -85.5% | +41.9% | -68.3% | -92.9% |
| 10-Year ReturnCumulative with dividends | -89.7% | +255.2% | +10.8% | -91.6% |
| CAGR (3Y)Annualised 3-year return | +10.8% | -12.4% | -23.7% | -56.4% |
Risk & Volatility
Evenly matched — RGS and IPAR each lead in 1 of 2 comparable metrics.
Risk & Volatility
IPAR is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RGS currently trades 88.9% from its 52-week high vs SKIN's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 0.54x | 1.73x | 2.00x |
| 52-Week HighHighest price in past year | $31.50 | $142.61 | $121.64 | $2.69 |
| 52-Week LowLowest price in past year | $17.50 | $77.21 | $57.91 | $0.76 |
| % of 52W HighCurrent price vs 52-week peak | +88.9% | +65.9% | +70.1% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 56.3 | 55.9 | 66.6 | 52.1 |
| Avg Volume (50D)Average daily shares traded | 9K | 259K | 4.6M | 760K |
Analyst Outlook
IPAR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: IPAR as "Hold", EL as "Hold", SKIN as "Hold". Consensus price targets imply 42.9% upside for SKIN (target: $1) vs 14.4% for IPAR (target: $108). For income investors, IPAR offers the higher dividend yield at 3.40% vs EL's 2.01%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | — | $107.50 | $106.73 | $1.30 |
| # AnalystsCovering analysts | — | 19 | 46 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | +3.4% | +2.0% | — |
| Dividend StreakConsecutive years of raises | 0 | 5 | 0 | — |
| Dividend / ShareAnnual DPS | — | $3.20 | $1.72 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.5% | +0.1% | 0.0% |
IPAR leads in 2 of 6 categories — strongest in Profitability & Efficiency and Analyst Outlook. 4 categories are tied.
RGS vs IPAR vs EL vs SKIN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RGS or IPAR or EL or SKIN a better buy right now?
For growth investors, Regis Corporation (RGS) is the stronger pick with 3.
5% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Regis Corporation (RGS) offers the better valuation at 0. 6x trailing P/E, making it the more compelling value choice. Analysts rate Inter Parfums, Inc. (IPAR) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RGS or IPAR or EL or SKIN?
On trailing P/E, Regis Corporation (RGS) is the cheapest at 0.
6x versus Inter Parfums, Inc. at 17. 9x. On forward P/E, Inter Parfums, Inc. is actually cheaper at 19. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — RGS or IPAR or EL or SKIN?
Over the past 5 years, Inter Parfums, Inc.
(IPAR) delivered a total return of +41. 9%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: IPAR returned +255. 2% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RGS or IPAR or EL or SKIN?
By beta (market sensitivity over 5 years), Inter Parfums, Inc.
(IPAR) is the lower-risk stock at 0. 54β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 267% more volatile than IPAR relative to the S&P 500. On balance sheet safety, Inter Parfums, Inc. (IPAR) carries a lower debt/equity ratio of 20% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — RGS or IPAR or EL or SKIN?
By revenue growth (latest reported year), Regis Corporation (RGS) is pulling ahead at 3.
5% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -391. 7% for The Estée Lauder Companies Inc.. Over a 3-year CAGR, IPAR leads at 11. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RGS or IPAR or EL or SKIN?
Regis Corporation (RGS) is the more profitable company, earning 58.
8% net margin versus -7. 9% for The Estée Lauder Companies Inc. — meaning it keeps 58. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IPAR leads at 18. 2% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — EL leads at 73. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RGS or IPAR or EL or SKIN more undervalued right now?
On forward earnings alone, Inter Parfums, Inc.
(IPAR) trades at 19. 4x forward P/E versus 38. 4x for The Estée Lauder Companies Inc. — 19. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SKIN: 42. 9% to $1. 30.
08Which pays a better dividend — RGS or IPAR or EL or SKIN?
In this comparison, IPAR (3.
4% yield), EL (2. 0% yield) pay a dividend. RGS, SKIN do not pay a meaningful dividend and should not be held primarily for income.
09Is RGS or IPAR or EL or SKIN better for a retirement portfolio?
For long-horizon retirement investors, Inter Parfums, Inc.
(IPAR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 3. 4% yield, +255. 2% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IPAR: +255. 2%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RGS and IPAR and EL and SKIN?
These companies operate in different sectors (RGS (Consumer Cyclical) and IPAR (Consumer Defensive) and EL (Consumer Defensive) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: RGS is a small-cap deep-value stock; IPAR is a small-cap deep-value stock; EL is a mid-cap quality compounder stock; SKIN is a small-cap quality compounder stock. IPAR, EL pay a dividend while RGS, SKIN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.